- CTIC Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
-
ETFs
- Insider
- Institutional
- Shorts
-
S-3 Filing
CTI BioPharma (CTIC) S-3Shelf registration
Filed: 25 Oct 11, 12:00am
EXHIBIT 12.l
STATEMENT RE: COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES AND OF
EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS
The following table sets forth our ratio of earnings to fixed charges and of earnings to combined fixed charges and preferred stock dividends for each of the periods indicated:
Nine months ended September 30, | Year ended December 31, | |||||||||||||||||||||||
2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||||||||||||||||||
Ratio of earnings to fixed charges(1) | — | — | — | — | — | — | ||||||||||||||||||
Ratio of earnings to combined fixed charges and | — | — | — | — | — | — |
(1) | Earnings were not sufficient to cover fixed charges or combined fixed charges and preferred stock dividends for each of the periods indicated. Earnings consist of income (loss) before provision for income taxes plus fixed charges. Fixed charges consist of interest charges and that portion of rental payments under operating leases we believe to be representative of interest. Earnings for the years ended December 31, 2010, 2009, 2008, 2007 and 2006 and for the nine months ended September 30, 2011 were insufficient to cover fixed charges, and fixed charges and preferred stock dividends, by $147.6, $116.8, $202.9, $148.3, $135.8 and $103.2 (in millions), respectively. For this reason, no ratios are provided for these periods. |